Cytokinetics (NASDAQ:CYTK) EVP Sells $270,795.00 in Stock

Key Points

• EVP Fady Ibraham Malik sold 3,500 shares on May 5 at an average price of $77.37 under a Rule 10b5‑1 plan for $270,795, cutting his stake to 153,902 shares (a 2.22% decrease) valued at about $11.9M.
• Cytokinetics announced positive topline results from the ACACIA‑HCM Phase‑3 trial and reported a Q1 revenue beat of $19.36M (vs. ~$8.5M expected) driven by early U.S. commercial sales (~$4.8M), prompting a sharp stock move and several analyst price‑target raises (consensus: Moderate Buy, avg target ≈ $92).
• The company also unveiled a proposed underwritten offering of roughly $650M of common stock, a potentially dilutive near‑term headwind that investors will weigh alongside recent insider selling.

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Fady Ibraham Malik sold 3,500 shares of the business's stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $77.37, for a total value of $270,795.00. Following the completion of the sale, the executive vice president directly owned 153,902 shares of the company's stock, valued at $11,907,397.74. This represents a 2.22% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Fady Ibraham Malik also recently made the following trade(s):

• On Tuesday, April 21st, Fady Ibraham Malik sold 3,500 shares of Cytokinetics stock. The stock was sold at an average price of $65.69, for a total value of $229,915.00.
• On Tuesday, April 7th, Fady Ibraham Malik sold 4,500 shares of Cytokinetics stock. The stock was sold at an average price of $65.11, for a total value of $292,995.00.
• On Tuesday, March 17th, Fady Ibraham Malik sold 12,033 shares of Cytokinetics stock. The stock was sold at an average price of $62.15, for a total value of $747,850.95.
• On Monday, March 9th, Fady Ibraham Malik sold 2,907 shares of Cytokinetics stock. The stock was sold at an average price of $60.72, for a total value of $176,513.04.

Cytokinetics Stock Performance

Shares of Cytokinetics stock traded up $11.04 during trading on Tuesday, reaching $77.09. The company's stock had a trading volume of 18,074,833 shares, compared to its average volume of 2,059,842. The business's fifty day moving average price is $63.81 and its 200-day moving average price is $63.53. The firm has a market cap of $9.58 billion, a price-to-earnings ratio of -11.81 and a beta of 0.38. Cytokinetics, Incorporated has a one year low of $29.31 and a one year high of $80.20.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported ($1.67) EPS for the quarter, hitting analysts' consensus estimates of ($1.67). The business had revenue of $19.36 million during the quarter, compared to the consensus estimate of $8.52 million. Sell-side analysts anticipate that Cytokinetics, Incorporated will post -6.31 EPS for the current year.

Key Stories Impacting Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Topline pivotal ACACIA‑HCM Phase‑3 results met both dual primary endpoints (KCCQ and maximal exercise performance), a major clinical validation that expands the aficamten label opportunity and supports long‑term revenue potential. ACACIA‑HCM results
• Positive Sentiment: Early U.S. commercial launch shows strong demand (over 275 HCPs prescribed an estimated ~680 patients in Q1) with net product revenues of $4.8M in the initial partial quarter; the EU approval and FDA supplemental NDA acceptance (PDUFA Nov 14, 2026) further de‑risk near‑term commercialization. Q1 results & business update
• Positive Sentiment: Q1 revenue materially beat expectations ($19.36M actual vs. ~$8.52M expected); EPS matched consensus (‑$1.67). The revenue beat reflects product sales and supports upward re‑rating. Revenue beat
• Positive Sentiment: Needham raised its price target to $102 and maintained a Buy, joining other analysts who have increased targets — a bullish signal from the sell side that can attract investor interest. Needham price target raise (Benzinga)
• Neutral Sentiment: Company reported ~ $1.1B in cash, cash equivalents and investments as of March 31, providing runway for commercialization and ongoing trials; investors should watch burn vs. expected commercialization spend. Cash balance
• Negative Sentiment: Cytokinetics announced a proposed underwritten offering of approximately $650M of common stock — likely dilutive and the main near‑term headwind; details (size, price, timing) will determine dilution and market impact. Proposed $650M offering
• Negative Sentiment: EVP Andrew Callos sold 15,857 shares (Rule 10b5‑1 plan) — disclosed insider selling can be viewed negatively by some investors even if pre‑arranged. Insider sale filing

Analysts Set New Price Targets

A number of equities analysts have recently commented on CYTK shares. B. Riley Financial lifted their price objective on Cytokinetics from $90.00 to $108.00 and gave the stock a "buy" rating in a research note on Wednesday, January 21st. Needham & Company LLC lifted their price objective on Cytokinetics from $85.00 to $102.00 and gave the stock a "buy" rating in a research note on Tuesday. Jefferies Financial Group reiterated a "buy" rating and issued a $90.00 price objective on shares of Cytokinetics in a research note on Friday, January 9th. UBS Group boosted their price target on Cytokinetics from $61.00 to $69.00 and gave the company a "neutral" rating in a research note on Friday, March 6th. Finally, Wells Fargo & Company initiated coverage on Cytokinetics in a research note on Friday, April 10th. They set an "overweight" rating and a $95.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Cytokinetics has a consensus rating of "Moderate Buy" and an average target price of $92.10.

Institutional Investors Weigh In On Cytokinetics

A number of institutional investors have recently added to or reduced their stakes in CYTK. Woodline Partners LP boosted its holdings in Cytokinetics by 676.1% during the third quarter. Woodline Partners LP now owns 1,647,725 shares of the biopharmaceutical company's stock valued at $90,559,000 after purchasing an additional 1,435,422 shares in the last quarter. Norges Bank acquired a new stake in Cytokinetics during the fourth quarter valued at approximately $51,281,000. Deep Track Capital LP boosted its holdings in Cytokinetics by 17.8% during the third quarter. Deep Track Capital LP now owns 4,300,000 shares of the biopharmaceutical company's stock valued at $236,328,000 after purchasing an additional 650,000 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in Cytokinetics by 151,987.4% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 565,765 shares of the biopharmaceutical company's stock valued at $35,949,000 after purchasing an additional 565,393 shares in the last quarter. Finally, Foresite Capital Management IV LLC acquired a new stake in Cytokinetics during the third quarter valued at approximately $25,188,000.

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company's most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.